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Background: Randomized controlled trials (RCTs) may be discontinued because of apparent harm, benefit, or
futility. Other RCTs are discontinued early because of insufficient recruitment. Trial discontinuation has ethical
implications, because participants consent on the premise of contributing to new medical knowledge, Research
Ethics Committees (RECs) spend considerable effort reviewing study protocols, and limited resources for conducting
research are wasted. Currently, little is known regarding the frequency and characteristics of discontinued RCTs.
Methods/Design: Our aims are, first, to determine the prevalence of RCT discontinuation for specific reasons;
second, to determine whether the risk of RCT discontinuation for specific reasons differs between investigator- and
industry-initiated RCTs; third, to identify risk factors for RCT discontinuation due to insufficient recruitment;
fourth, to determine at what stage RCTs are discontinued; and fifth, to examine the publication history of
discontinued RCTs.
We are currently assembling a multicenter cohort of RCTs based on protocols approved between 2000 and
2002/3 by 6 RECs in Switzerland, Germany, and Canada. We are extracting data on RCT characteristics and
planned recruitment for all included protocols. Completion and publication status is determined using information
from correspondence between investigators and RECs, publications identified through literature searches,
or by contacting the investigators. We will use multivariable regression models to identify risk factors for trial
discontinuation due to insufficient recruitment. We aim to include over 1000 RCTs of which an anticipated 150
will have been discontinued due to insufficient recruitment.
Discussion: Our study will provide insights into the prevalence and characteristics of RCTs that were discontinued.
Effective recruitment strategies and the anticipation of problems are key issues in the planning and evaluation of
trials by investigators, Clinical Trial Units, RECs and funding agencies. Identification and modification of barriers to
successful study completion at an early stage could help to reduce the risk of trial discontinuation, save limited
resources, and enable RCTs to better meet their ethical requirements.
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Randomized clinical trials (RCTs) are the optimal study
design to establish the efficacy of therapeutic or pre-
ventive interventions, and are a cornerstone in drug
development and comparative effectiveness research.
Conducting high-quality RCTs is a challenging and
resource-demanding endeavour that usually involves
multiple stakeholders including clinical researchers,
patients and patient interest groups, funding agencies,
pharmaceutical companies, research ethics committees
(RECs), and regulatory agencies.
Many unforeseen events can occur during the course
of an RCT. Consequently, it is not surprising that they
are often not conducted as initially planned or are pre-
maturely discontinued.
Reasons for discontinuation of RCTs include unantici-
pated adverse effects (harm) [1], larger than expected
benefit of an intervention (early superiority) [2], or a
very low probability of detecting a designated treatment
effect with continued patient recruitment or follow-up
(futility) [3]. RCTs may be discontinued because the
sponsor withdraws funding for strategic or administra-
tive reasons, or because new evidence from other studies
may convincingly answer the primary research question
or raise serious safety issues [4]. Finally, RCTs are some-
times discontinued for practical reasons of insufficient
recruitment of participants. To date the prevalence of
trial discontinuation for any of these reasons cited above
has not been determined. It also remains unknown
whether the prevalence for specific reasons differs between
trials initiated by investigators and those initiated by
the industry.
Discontinued trials due to insufficient recruitment
Difficulties in patient recruitment may necessitate
amendments to the protocol. These may include pro-
longation of the recruitment period, broadening of inclu-
sion criteria, addition of recruiting centres, or modifying
the outcomes of interest. Some studies highlighted
the high frequency of recruitment problems in RCTs
(Table 1) [5-10]. However, these studies only report
recruitment problems of specific trials [7,8], were based
on published data [10] or the selection of trials investi-
gated were restricted to a specific funding source [5,6].
Easterbrook et al. employed a review of study protocols
[6] comparable to our approach described herein, but
the data are now almost 20 years old.
Investigators have studied patients’ attitudes to trial
participation [11-13] and identified multiple barriers
[14-16]. In general, patients view clinical trials as im-
portant, ethical, and as a means of attaining superior
health care for future patients. However, when asked
about their own participation, responders expressed
more self-concern and less altruism [11]. Randomizationor inclusion of a placebo arm can deter eligible patients
from entering a trial [13]. Other barriers to patient
participation include fear of side effects, distrust of
researchers, inconvenience to everyday life, complexity
of protocols, fear of deterioration of the relationship
with their physician, and unawareness of trial opportun-
ities [14,15].
In turn, attending physicians report the following bar-
riers to an active role in trials: time constraints, lack
of staff and training, worry about the impact on their
relationship with patients, concern for patients, loss of
professional autonomy, difficulty with the consent pro-
cedure, and lack of any reward, recognition or interest in
the research question [16].
Recent research has focused on strategies of how
recruitment can be improved in different settings of
clinical research [17-19] and systematic reviews on the
topic have identified several interventions, e.g. increas-
ing awareness of the health problem being studied,
monetary incentives, using an ‘open label’ rather than
placebo design, or making trial materials culturally sensi-
tive [20-22]. Another recent systematic review empha-
sized the use of qualitative methods in order to identify
and overcome barriers to the recruitment activity of
clinicians [23]. While trial discontinuation for apparent
benefit has been investigated previously [24,25], little
is known about the epidemiology and features of trials
discontinued for other reasons, in particular for insuffi-
cient recruitment.
Ethical considerations with discontinued trials
Trial discontinuation poses ethical problems. Firstly,
study participants consent on the premise of contri-
buting to the advancement of medical knowledge. The
International Committee of Medical Journal Editors
(ICMJE) argues that “patients who volunteer to partici-
pate in clinical trials deserve to know that their contri-
bution to improving human health will be available to
inform health-care decisions” [26]. If trials are stopped,
participants should be informed about this decision and
the associated reasons. However, such information may
not always be given and follow-up of already recruited
participants after trial discontinuation may not always
be guaranteed.
Secondly, RECs face high workloads in reviewing the
protocols of planned studies. However, many RECs are
under-staffed and their members serve on a voluntary
basis on top of their professional duties. RECs should be
enabled to identify trial projects that stand a good
chance of successful completion and thereby merit the
investment of a thorough review by a multidisciplinary
panel. According to Article 15 of the Helsinki Declar-
ation, RECs are also entitled to monitor the progress of
approved studies [27]. However, many of them may not
Table 1 Examples of studies reporting about recruitment problems in randomized controlled trials (RCTs)
Authors Year Data Source Findings
Charlson et al. 1984 41 RCTs (≥ 250 patients) identified by an inventory
of the National Institute of Health in 1979; investigator
survey was principal data source
A third of RCTs recruited fewer than 75% of their
planned sample size
Easterbrook et al. 1992 720 research protocols (N = 137 RCTs) approved by
REC (UK); investigator survey was principal data source
Main reason (28%) for terminating the study was
slow recruitment of patients
Wilson et al. 2000 RCT that investigated two management strategies for
dyspepsia in primary care (UK)
90 primary care physicians were contacted;
43 agreed to participate, 31 recruited at least one
patient, only 23 recruited more than 5 patients.
Foy et al 2003 7 primary care trials of dyspepsia management in
the UK
One study reached its recruitment target; five
recruited less than 50% of target and three of
those closed prematurely
McDonald et al. 2006 114 RCTs funded by the Medical Research Council
and Health Technology Assessment (UK); full scientific
applications and subsequent trial reports were
principal data source
Less than a third of the trials achieved their original
recruitment target
Toerien et al. 2009 133 publications of RCTs identified by a systematic
literature review (restricted to six major journals)
Of those trials reporting sample size calculation,
21% failed to achieve planned numbers at
randomisation and 48% at outcome assessment.
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requests to applicants to submit final reports or publica-
tions resulting from their research.
Thirdly, resources available for research are limited,
particularly in the case of publicly funded research. Con-
siderable waste can occur if costly RCTs need to be dis-
continued because assumptions about recruitment or
other feasibility issues were over-optimistic [28].
Fourthly, trialists should be open about the difficulties
that were encountered in failed RCTs and make their
experiences available to the scientific community, in par-
ticular if the research was publicly funded. Publication
of results from clinical research has been described as an
“ethical imperative” [29], and in addition to data from
completed studies, it has been proposed that this
should also comprise information about research proto-
cols [30]. Public access to trial protocols and publica-
tion of discontinued trials is thus of high importance to
help preventing replications of unsuccessful approaches
and allow the inclusion of data from discontinued
trials in systematic reviews. Reports of discontinued
trials are available in published literature [31-34] but
remain exceptions.
A comprehensive research effort using empirical meth-
ods is necessary to better understand RCT discontinu-
ation, to meet the associated ethical challenges, and to
develop guiding principles for involved stakeholders.
Study objectives and hypotheses
We use REC-approved RCT protocols and correspond-
ing publications to investigate the prevalence, character-
istics, and publication history of RCTs that were
discontinued for different reasons, and to identify risk
factors for RCT discontinuation, in particular for studiesdiscontinued due to insufficient recruitment. The spe-
cific objectives and hypotheses are:
1. To determine the risk of RCTs to be discontinued for
any reason and for specific reasons including futility,
adverse events, early superiority of one intervention,
and insufficient recruitment (defined for primary
analysis as <90% of the planned sample size achieved,
and for secondary analysis as <80%).
Hypothesis: The prevalence of discontinued trials
among approved trials ranges from 10% to 20%;
insufficient recruitment of study participants is the
most frequent reason for discontinuation.
2. To determine whether the risk of trial
discontinuation for specific reasons will differ for
investigator- versus industry-initiated trials.
Hypothesis: The risk for discontinuation due to
insufficient recruitment is lower for industry-initiated
trials.
3. To identify characteristics of study protocols
associated with premature discontinuation of RCTs
due to insufficient recruitment from a list of
candidate variables (Table 2). These risk factors may
be modifiable or non-modifiable.
Hypothesis: The more risk factors and the less
protective factors are identified in a protocol, the
higher the risk for discontinuation.
4. To determine the timing of discontinuation relative
to the recruitment goals.
Hypotheses: a) Trials discontinued for futility
are typically stopped at an advanced stage of
the recruitment process (>60% of target sample
size recruited); b) Trials exclusively discontinued
due to insufficient recruitment are typically
Table 2 Potential risk factors and protective factors for trial discontinuation due to slow recruitment
Modifiable factors Non-modifiable Factors
Risk Protective Risk Protective
Burdensome data collection at
recruiting sites
Support from a methods centre,
clinical trials unit, or contract
research organization
Placebo control Active treatment as control
No professional staff at recruiting
centres to manage the trial
Paid local staff at recruiting centres,
dedicated central trial coordinator,
patient involvement in trial planning
and/or conduct
No external funding Externally funded or fully
Industry sponsored
No projection of recruitment rates Projection of patient recruitment
based on e.g. pilot trial applying the
full protocol or other checks for
eligible patient volume
Long duration of follow-up Short duration of follow-up /
High community interest in
research topic (e.g. new technology
or new treatment)
No consideration of recruitment
strategies
Consideration of recruitment support
strategies (e.g. regular visits/audits by PI;
specific training held for recruiting staff;
regular progress reports; posters and
information leaflets etc.)
No research network, low trial
experience
Experienced PI/steering committee/
network of recruiting centres for
RCTs
Single centre trial Multicentre trial Equivalence/non-inferiority design Intervention only available through
trial participation
Low motivation for recruiting sites Financial incentives for recruiting staff
and participants
Critically ill or paediatric patients
as target population
Trial experience with certain
vulnerable trial populations
Kasenda et al. BMC Medical Research Methodology 2012, 12:131 Page 4 of 10
http://www.biomedcentral.com/1471-2288/12/131stopped at an earlier stage (<60% of target sample
size recruited).
5. To examine the publication history of discontinued
trials and to assess to what extent lessons learnt have
been disseminated through formal publications,
unpublished reports, databases or trial registers.
Hypotheses: a) Information from discontinued trials
is rarely made available to others by formal
publication or other forms of dissemination. b) In
case of a significant result at the time of
discontinuation, the results are more frequently
published in a peer-reviewed journal.
Study design and methodology
The present study addressing DISCOntinuation of RCTs
(DISCO-study) is a multi-centre empirical research pro-
ject that involves 4 RECs in Switzerland (Basel, Lucerne,
Zurich, and Lausanne), 1 in Germany (Freiburg), and
1 in Canada (Hamilton). We have established research
partnerships with each REC to access the RCT protocols
approved by them between 2000 and 2003. The confi-
dentiality of the filed study protocols is being maintained
following the framework and rationale for this type
of research as proposed earlier [35].
Eligibility criteria
The DISCO-study is based on protocols of all approved
clinical trials that allocated participants prospectively
and concurrently to comparison groups by random or
quasi-random methods of allocation (such as alternation,
date of birth, or case record number) and comparedone or several interventions with a placebo or sham
intervention, another active intervention or no interven-
tion. Studies comparing different doses or routes of
administration of the same drug (early dose-finding
studies), trials enrolling only healthy volunteers, or trials
labeled as pilot or feasibility studies are included as pre-
specified subgroups.
Selection process
All study protocols approved by one of the 6 RECs be-
tween January 1st 2000 to December 31st 2002/3 will be
screened for eligibility. For the purpose of the DISCO-
study, we chose to sample protocols approved around
9 years ago to ensure that only a very small proportion of
RCTs would be still ongoing at the time of our study [25].
Definition and identification of discontinued trials
The main outcome of interest is RCT discontinuation.
We define a ‘discontinued RCT’ as any RCT that was
stopped before reaching at least 90% of the planned
sample size due to any reason, including futility, adverse
events (harm), early evidence of superiority of one inter-
vention (benefit) and insufficient recruitment (a cut-off
at 80% of the planned sample size will be considered in
a sensitivity analysis). We use the following sources to
identify discontinued trials:
 Internal REC reports on status or progress of
approved studies,
 Correspondence between applicants and RECs with
information about discontinuation,
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trials used by the participating RECs,
 Any formal publication mentioning trial
discontinuation,
 Directly contacting investigators about the status of
the RCTs
Data to be extracted
We extract data on relevant trial characteristics from
protocols of eligible trials as follows:
Core protocol data
1. Centre and protocol information (e.g. local archive
identification number, date of approval by REC)
2. Contact data of local and overall principal
investigator (to enable contact with applicants
through the local REC)
3. Trial properties (e.g. study design, number of centres,
detailed information about interventions)
4. Trial funding (e.g. government, private for profit)
5. Any important changes/amendments to the
protocol during the course of the trial (mainly
extracted from correspondence between REC
and applicant)
6. Main endpoints: Completion and publication status
(e.g. trial stopped early for insufficient recruitment,
trial published)
Specific protocol data
1. Clinical area (e.g. medical or surgical)
2. Setting of the trial (e.g. outpatient clinic, intensive
care unit)
3. Age group of participants
4. Primary outcomes
5. Statistical analysis (e.g. planned primary analysis,
intention to treat, dealing with losses to follow up)
6. Subgroups (e.g. pre-specification of subgroups)
7. Sample size, recruitment and data safety issues (e.g.
planned total sample size, interim analysis, data
safety monitoring board)
8. Projection of recruitment during planned
enrollment time (e.g. milestones or time schedule
for patient recruitment)
9. Availability of logistic/methodological support (e.g.
trial support unit, structure of trial organization,
paid staff at recruiting sites)
10. Strategies to support/monitor recruitment (e.g.
regular newsletters, advertisement in newspapers,
financial incentives)
11. Trial initiation and publication/stopping rules (e.g.
industry or investigator initiated, publication
constraints, sponsor rights to stop the trial)Data extraction process
We use a web-based password-protected database
(Squiekero, www.squiekero.org) for data extraction. A
manual with definitions and rules for data extraction for
each variable has been compiled, updated and shared
among all staff involved in data extraction at the 6 study
sites. About 15 methods-trained investigators extract
data from trial protocols. The course of action is illu-
strated in Figure 1 and listed in Table 3.
We conduct calibration exercises in which extracted
data from several protocols will be compared and thor-
oughly discussed in order to ensure consistency between
the investigators. This process is crucial given that some
of the variables to be extracted require personal judge-
ment. We plan to extract 30% of eligible protocols inde-
pendently and in duplicate and conduct random checks
for consistency in remaining protocols.
Search for publications
If no information about the publication status of a trial
is given in the REC files, we conduct electronic searches
in literature databases including Medline, Embase, Goo-
gle Scholar, Cochrane CENTRAL register of clinical
trials, CINAHL, AMED, and topic specific databases.
We also search trial registers such as ClincialTrials.gov,
ISRCTN, the WHO International Clinical Trials Registry
Platform and registers of sponsors, if publicly available.
We use key words from the protocol title and interven-
tions, study acronyms, and names of the investigators as
search terms. Depending on the database, we limit the
searches to randomized trials in humans and take into
account possible time of publication. If potential publi-
cations are found, we attempt to identify the main publi-
cation of the trial by retrieving the full text. We also
check whether the main publication refers to other pub-
lications of the trial (especially rationale and design
papers). From the included publications, 2 investigators
extract data independently and in duplicate on the fol-
lowing topics: author and publication information, trial
properties, study funding, clinical area, methodological
quality, enrolment and follow-up, outcomes, analysis,
subgroups, and sample size/recruitment.
Risk factor analysis for discontinuation due to
insufficient recruitment
In a sub-study, we will compare trials that were discon-
tinued due to insufficient recruitment with completed
trials. From this subgroup, we will exclude trials that
(i) used cluster randomization (because they differ from
trials that randomize individuals in issues of
recruitment), (ii) are still ongoing in 2012, and (iii) have
unclear completion status or reasons for discontinua-
tion other than insufficient recruitment. Trials that
were discontinued due to insufficient recruitment will be
Figure 1 Workflow of the DISCO study. RCT, randomized controlled trial; REC, research ethics committee.
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“controls”.
Data management and statistical analysis
Data management and database cleaning will be carried
out using R version 2.15.1 (The R project for statistical
computing, www.r-project.org). We will read the defini-
tive dataset into STATA (version 12.1, STATA Corpor-
ation, Austin/Texas, USA) for statistical analyses. TheTable 3 Steps for identification of discontinued trials and
data extraction; REC, regional ethics committee
Steps Actions
1 Identification of protocols of RCTs submitted 2000 to 2002
with the help of REC staff members
2 Extraction of trial characteristics from eligible protocols
and attempt to clarify completion of trials through filed
correspondence between the REC and applicants
3 Electronic search for publications (e.g. MEDLINE, EMBASE,
Google Scholar) of eligible trials using filed information
such as key words from protocol title/intervention or
names of investigators
4 REC in charge will contact the applicants using a standardized
questionnaire to ask about reasons of discontinuation and
the availability of any formal publications, unpublished reports
or other information from eligible trials (only in case trial
completion and publication status remain unknown after
searching filed correspondence and comprehensive publication
search)
5 The REC in charge may send several reminders or contact
applicants by phone if necessary
6 After receiving responses from applicants the data collection
process will be finalized
7 The analysis database will contain only anonymous data
with trial identification numbersreasons for trial discontinuation will be analysed using
descriptive statistics, including risks (cumulative inci-
dences) of discontinuation expressed as percentage with
95% confidence intervals. In the sub-study on trial dis-
continuation due to insufficient recruitment, potential
risk factors (hypothesis 3) will be analysed using multi-
variate hierarchical logistic regression models with
protocol-level variables as fixed effects and the ‘par-
ticipating centers’ (i.e. the RECs) as a random effect.
This approach will account for variability from two
sources, i.e. within and between centers. To minimize
the risk of overfitting and data-driven associations, we
have pre-specified risk factors and confounding variables
for the statistical model and limited their number to
obtain no less than 10 events (i.e. discontinued trials)
per explanatory variable in the resulting multivariable
logistic regression models [36].
Risk factors will include: Placebo/no treatment control
versus active intervention, single center versus multicen-
ter trial, no or inadequate versus adequate projection
of recruitment during planned enrolment period, and
absence versus presence of methodological/logistical
support. Potential confounders will include: presence
versus absence of industry funding/involvement, parallel
versus cross-over/factorial trial, and the planned total
number of participants.
We will calculate odds ratios with 95% confidence
intervals. Statistical test results with two-sided P < .05
will be regarded as significant. We expect that the pro-
portion of missing data for the above specified variables
will be low because the information to be collected from
a trial protocol is either very basic or it is about the
presence or absence of information in the protocol (e.g.
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site investigators for clarifications/missing information if
necessary. In our primary analysis, we will only consider
protocols with complete data (complete cases analysis).
In a second step, missing data will be imputed using
multiple imputation techniques; based on this imputed
dataset, we will conduct a sensitivity analysis (all case
analysis). Furthermore, we will conduct bootstrapping
for internal model validation.
Estimated sample size
In a previous study, protocols of randomized drug trials
submitted between 1989 and 1998 were analysed [37].
Fifty-seven of 531 trials (11%) were discontinued for dif-
ferent reasons. In 22 cases (39%) the reason was insuffi-
cient recruitment of participants. In the cohort of trials
established in Freiburg (Germany), 74 of 299 studies
submitted in 2000 (25%) were discontinued [38]. Taking
into account these results and the available literature
[39,40] we estimate that about 10% to 20% of trials
started are discontinued due to insufficient recruitment.
Based on information by the collaborating RECs and
published data, we anticipate that we will identify over
1000 eligible RCT protocols approved by the participat-
ing RECs between 2000 and 2002/3 and that about 15%
of these RCTs were discontinued due to insufficient
recruitment. Under the assumption of a minimal odds
ratio to be detected of 2.0 and 150 of 1000 RCTs to be
stopped due to insufficient recruitment, we calculated
the power to detect such an association between an
exposure factor (e.g. single centre status) and the binary
outcome of discontinuation due to insufficient recruit-
ment. As an example, the power to detect an association
for an exposure factor is 88% if the prevalence of this
factor in the “control trials” is 20% (Table 4). Therefore
a sample size of 1000 protocols should be sufficient for
our planned analyses.
Discussion
The DISCO study will determine the prevalence of
RCTs discontinued for a variety of reasons, differences
between industry and investigator-initiated RCTs, riskTable 4 Power calculations for different prevalences of a
single risk factor for trial discontinuation; RCT,
randomized controlled trial; OR, odds ratio
Prevalence (%) of risk factor
Completed
RCTs
RCTs discontinued
due to slow accrual
Study power (%)
to detect OR=2.0
10 18 65
20 33 88
30 46 95
40 57 96factors for discontinuation due to insufficient recruit-
ment from RCT protocols, the stage at which RCTs
are discontinued, and examine the publication history
of completed and discontinued RCTs. To achieve these
goals a cohort of over 1000 RCTs in various med-
ical fields will be established based on the protocols
approved at participating RECs over a four-year time
period. Through this publication we intend to make our
study objectives and methods transparent [41].
Strengths and limitations of the protocol
In this empirical study we use robust methodology in-
cluding a transparent and systematic process to identify
eligible RCTs, to extract relevant characteristics from
protocols, and to search for corresponding publica-
tions. The collaboration with 6 RECs in 3 different coun-
tries should enhance the generalizability of our results.
Approximately 1000 RCTs will provide sufficient statis-
tical power for the planned analyses and likely repres-
ent one of the largest cohorts in the field of empirical
trial research.
The rigor of our study depends not only on the level
of detail and quality of protocols, but also on the com-
pleteness of the correspondence and amendments
between the investigator and the REC. We will systemat-
ically search these files to capture any relevant informa-
tion about the course of the trial, as well as on issues of
recruitment or changes in design or modification of pri-
mary endpoints. In case we are not able to evaluate the
completion or publication status of the trial based on
the filed documents at the local REC, applicants or prin-
cipal investigators will be contacted through local RECs.
Experience from one of our previous projects suggests
that most applicants will respond [38].
Beyond discontinued trials
The DISCO-study offers the possibility to investigate
discrepancies between protocols and subsequent publi-
cations e.g. with regard to pre-specified and reported
primary endpoints, statistical analyses, or sample size.
As an example, judging the credibility of subgroup
effects when reading trial publications is challenging
and, following recent recommendations, it is crucial to
pre-specify anticipated subgroup effects before the ana-
lysis [42]. The DISCO-study will allow investigations
about the planning and reporting of subgroup analyses
in RCTs from various medical fields.
Comparison with similar studies and protocols
The STEPS study was an epidemiological survey of 114
RCTs funded by the UK Medical Research Council and
Health Technology Assessment (HTA) Programme [28].
Less than one-third of included trials recruited their ori-
ginal target number of patients within the time originally
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sample size more frequently had a dedicated trial man-
ager, were cancer or drug trials, or offered treatments to
patients exclusively available within the trial. The most
commonly reported strategies to improve recruitment
were newsletters and Email reminders, but the investiga-
tors could not determine whether these measures were
causally linked to changes in recruitment [28].
In contrast to the STEPS study, our database will con-
sist of RCTs that were not funded by a single agency but
funded by various sponsors and sources including the
industry, public, and in-house sources of university-
affiliated hospitals. We will determine if the risk factors
identified in the STEPS study can be reproduced within
our more diverse and much larger trial cohort.
The recruitment performance of local sites within a
multicentre trial is the key to successful trial completion.
Recently, Dal-Ré et al. proposed the disclosure of
recruitment performance of local sites within multicen-
tre trials in publicly available trial registries [43]. The ra-
tionale is that this would render the trial recruitment
process more transparent and trialists more account-
able, because their recruitment performance could be
followed by patient organizations, sponsors, and the
scientific community. The DISCO-study captures the
recruitment goals of the local site and the total across all
study sites, which will allow further insights into these
important planning issues.
The recently finished IMPACT-study by Oude et al.
(personal communication), investigated barriers and facili-
tators for successful patient recruitment to gynecology/
obstetrics trials in the Netherlands [44]. The group estab-
lished a nationwide cohort of trials with recruiting physi-
cians being interviewed about crucial determinants of
recruitment at a center level. Furthermore, using a
nested case–control design, they interviewed patients
who refused or consented to participate in order to iden-
tify factors associated with their decision. In a second
cohort study, the group investigated the association
between successful recruitment and issues such as
hospital organization and design of trials prospectively
registered in the Netherlands Trial Register. This study,
especially the latter part, has goals similar to ours. How-
ever, the methods and study population to identify risk
factors are different. In IMPACT, data about potential
risk factors were gathered through a questionnaire while
we use data from approved protocols; and we focus
exclusively on RCTs whereas IMPACT included non-
randomized studies as well. The IMPACT investigators
also outlined a problem regarding generalizability of
potentially identified risk factors for insufficient recruit-
ment which also applies to our protocol: on a patient
level, participation or non-participation in a clinical trial
might predominantly depend on characteristics of a trialand its target population; therefore overall predictors for
insufficient recruitment may not be identified. We may
consider this issue in sensitivity analyses e.g. through
stratification by medical field. However, full data collec-
tion will demonstrate the number of events of interest;
this will limit the number of variables that can be investi-
gated in multivariable logistic regression models.Implications and significance
The DISCO-study will provide important insights into
the prevalence and features of RCTs that were discontin-
ued for different reasons. RCTs are highly resource
demanding endeavours with stakeholders including
patients, clinicians, investigators, funding agencies, and
industry. Effective recruitment strategies and the antici-
pation of problems are key issues in the planning and
evaluation of trials by investigators, Clinical Trial Units,
RECs and funding agencies. With the identification of
potential barriers to successful study completion, the
DISCO-study will help reduce the risk of premature trial
discontinuation and save limited research resources. Fur-
thermore, as outlined in the Ottawa Statement [30],
RCTs imply ethical obligations to research participants.
When consenting to a trial, participants accept the
potential of harm that may occur to them. Their risk of
harm is primarily counterbalanced by the presumed
overall social good resulting from the advancement of
medical knowledge. We anticipate that evidence from
the DISCO-study will underpin the current efforts to en-
hance the transparency, standardisation and accessibility
of trial information. Such improvements are crucially
needed to meet the ethical obligations of RCTs and to
prevent that a decline in numbers of volunteering parti-
cipants will ultimately make clinical research impossible.
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